Redefining YAP1 in small cell lung cancer: shifting from a dominant subtype marker to a favorable prognostic indicator.

IF 4 2区医学 Q2 ONCOLOGY

Translational lung cancer research Pub Date : 2024-08-31 Epub Date: 2024-08-17 DOI:10.21037/tlcr-24-317

Se-Il Go, Jung Wook Yang, Eun Jeong Jeong, Woo Je Lee, Sungwoo Park, Dae Hyun Song, Gyeong-Won Lee

{"title":"Redefining YAP1 in small cell lung cancer: shifting from a dominant subtype marker to a favorable prognostic indicator.","authors":"Se-Il Go, Jung Wook Yang, Eun Jeong Jeong, Woo Je Lee, Sungwoo Park, Dae Hyun Song, Gyeong-Won Lee","doi":"10.21037/tlcr-24-317","DOIUrl":null,"url":null,"abstract":"Background: Molecular and transcription factor subtyping were recently introduced to identify patients with unique clinical features in small cell lung cancer (SCLC). However, its prognostic relevance is yet to be established. This study aims to investigate the clinical implications and prognostic significance of transcription factor subtyping in SCLC using immunohistochemistry.Methods: One hundred and ninety consecutive SCLC patients treated with platinum-based chemotherapy at a single institution were retrospectively reviewed. Expression of ASCL1, NeuroD1, POU2F3, and YAP1 was assessed by immunohistochemical staining and applied to determine the transcription factor subtype of each case.Results: The association among transcription factors was not entirely mutually exclusive. YAP1 expression was the most significant prognostic indicator compared with other transcription factors or their related subtypes. Among patients with limited-stage disease (LD), complete response (CR) rates were 46.2% and 22.4% in the YAP1-positive and YAP1-negative groups, respectively. The median duration of response among patients who achieved CR was 64.8 and 36.4 months in the YAP1-positive and YAP1-negative groups, respectively (P=0.06). Median overall survival (OS) in LD was 35.6 and 16.9 months in the YAP1-positive and YAP1-negative groups, respectively (P=0.03). In extensive-stage disease (ED), the median OS was 11.3 months for the YAP1-positive group and 11 months for the YAP1-negative group (P=0.03).Conclusions: Positive expression of YAP1 can be associated with durable CR and favorable survival outcomes in patients with SCLC, especially in LD.","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384494/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-24-317","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Molecular and transcription factor subtyping were recently introduced to identify patients with unique clinical features in small cell lung cancer (SCLC). However, its prognostic relevance is yet to be established. This study aims to investigate the clinical implications and prognostic significance of transcription factor subtyping in SCLC using immunohistochemistry.

Methods: One hundred and ninety consecutive SCLC patients treated with platinum-based chemotherapy at a single institution were retrospectively reviewed. Expression of ASCL1, NeuroD1, POU2F3, and YAP1 was assessed by immunohistochemical staining and applied to determine the transcription factor subtype of each case.

Results: The association among transcription factors was not entirely mutually exclusive. YAP1 expression was the most significant prognostic indicator compared with other transcription factors or their related subtypes. Among patients with limited-stage disease (LD), complete response (CR) rates were 46.2% and 22.4% in the YAP1-positive and YAP1-negative groups, respectively. The median duration of response among patients who achieved CR was 64.8 and 36.4 months in the YAP1-positive and YAP1-negative groups, respectively (P=0.06). Median overall survival (OS) in LD was 35.6 and 16.9 months in the YAP1-positive and YAP1-negative groups, respectively (P=0.03). In extensive-stage disease (ED), the median OS was 11.3 months for the YAP1-positive group and 11 months for the YAP1-negative group (P=0.03).

Conclusions: Positive expression of YAP1 can be associated with durable CR and favorable survival outcomes in patients with SCLC, especially in LD.

查看原文本刊更多论文

重新定义小细胞肺癌中的 YAP1：从主要亚型标志物转变为有利的预后指标。

背景：最近引入了分子和转录因子亚型，以识别具有独特临床特征的小细胞肺癌（SCLC）患者。然而，其预后相关性尚未确定。本研究旨在利用免疫组化技术研究转录因子亚型对小细胞肺癌的临床影响和预后意义：方法：对在一家机构接受铂类化疗的 190 例 SCLC 患者进行了回顾性研究。通过免疫组化染色评估 ASCL1、NeuroD1、POU2F3 和 YAP1 的表达，并应用于确定每个病例的转录因子亚型：结果：转录因子之间的关联并非完全相互排斥。与其他转录因子或其相关亚型相比，YAP1的表达是最重要的预后指标。在局限期疾病（LD）患者中，YAP1阳性组和YAP1阴性组的完全缓解率（CR）分别为46.2%和22.4%。在获得 CR 的患者中，YAP1 阳性组和 YAP1 阴性组的中位反应持续时间分别为 64.8 个月和 36.4 个月（P=0.06）。在LD患者中，YAP1阳性组和YAP1阴性组的中位总生存期（OS）分别为35.6个月和16.9个月（P=0.03）。在广泛期疾病（ED）中，YAP1阳性组的中位生存期为11.3个月，YAP1阴性组为11个月（P=0.03）：结论：YAP1阳性表达与SCLC患者（尤其是LD患者）的持久CR和良好生存预后相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational lung cancer research Medicine-Oncology

CiteScore

7.20

自引率

2.50%

发文量

137

期刊介绍： Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.